Prenetics Executives Invest $1.3M in Shares Post-Earnings, Cumulative Insider Buys Reach $2.7M
PRE has more than doubled off its 52-week low of $3.095.
Summary
Prenetics Global executives have executed a second consecutive round of open market share purchases, investing $1.3 million in the past week, bringing their cumulative personal investment across two post-earnings windows to $2.7 million. This follows the company's recent announcement of record Q4 and full-year 2025 financial results and the strategic sale of a stake in Insighta for $70 million, both reported in mid-February. The repeated insider buying, particularly from CEO Danny Yeung who increased his personal investment, signals strong management confidence in the company's future performance and valuation, reinforcing the positive momentum from recent operational successes. This action could bolster investor sentiment and suggests executives believe the stock is currently undervalued.
At the time of this announcement, PRE was trading at $15.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $266.6M. The 52-week trading range was $3.09 to $22.86. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.